The Immunological Basis for the Development of Tumor Cell- and Peptide-Based Vaccines for Treatment of Patients with Renal Cell Carcinoma
The failure of metastatic renal cell carcinoma (RCC) to respond to irradiation, chemotherapy or hormone therapy has left immunotherapy as the most hopeful form of treatment to date. Systemic cytokine therapy of RCC using recombinant interleukin-2 (rIL-2) alone or in combination with recombinant interferon-α (rIFN-α) has led to objective response rates of 20%–30% (Belldegrun et al. 1991; Rosenberg 1992). Nevertheless, few complete and long-lasting remissions have been achieved and severe toxic side effects limit their broad application. These obstacles have spurred efforts to develop alternative strategies to modulate immune responses of RCC patients. In particular, new approaches are sought for treatment of patients with minimal residual disease. In the forefront are attempts to develop genetically engineered tumor cell vaccines and peptide vaccines that will induce tumor-specific immune responses in vivo.
KeywordsOncol Interferon Hunt Noma Haas
Unable to display preview. Download preview PDF.
- Anonymous, (1996) Clinical protocols: cytokine/immunotherapy. Cancer Gene Ther 3:58–68Google Scholar
- Jantzer P, Oberneder R, Maget B, Schendel DJ (1995) Recruitment of MHC-restricted cytotoxic T lymphocytes specific for renal cell carcinoma to the tumor in situ. In: Bukowski RM, Finke JH, Klein EA (eds) Biology of renal cell carcinoma. Springer, Berlin, Heidelberg, New York, pp 84–93Google Scholar
- Jantzer P, Schendel DJ (1997) Immunosurveillance against spontaneously arising human renal cell carcinomas: antigen-driven selection in the T cell receptor repertoire of tumor-infiltrating lymphocytes in vivo. Submitted.Google Scholar
- Nossner E, Schendel DJ (1997) Autologous and allogeneic tumor cell vaccines. In: Blankenstein T, Herrmann F (eds) Gene therapy: principles and applications. Chapman and Hall, WeinheimGoogle Scholar
- Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Rieth-muller G, Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209–4220PubMedGoogle Scholar
- Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: Modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous a interferon treatment. Cancer Res 53:4020–4025PubMedGoogle Scholar
- Schendel DJ, Oberneder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmiiller G, Nößner E (1997) Cellular and molecular analyses of major histocompatability complex (MHC)-restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med (in press)Google Scholar